Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
24.50
+0.70 (2.94%)
At close: May 1, 2026, 4:00 PM EDT
24.49
-0.01 (-0.04%)
After-hours: May 1, 2026, 7:15 PM EDT
Evommune Revenue
In the year 2025, Evommune had annual revenue of $13.00M with 85.71% growth.
Revenue (ttm)
$13.00M
Revenue Growth
+85.71%
P/S Ratio
67.88
Revenue / Employee
$270,833
Employees
48
Market Cap
882.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.00M | 6.00M | 85.71% |
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEVMN News
- 19 days ago - Evommune Transcript: Status update - Transcripts
- 26 days ago - Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine - Business Wire
- 2 months ago - Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Business Wire
- 2 months ago - Evommune Announces $125 Million Private Placement - Business Wire
- 2 months ago - Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Benzinga
- 2 months ago - Evommune's Stock Surges On Strong Results For New Eczema Drug - Benzinga
- 2 months ago - Evommune Transcript: Study result - Transcripts
- 2 months ago - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Business Wire